---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-101492"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2026-09-18T21:11:43+00:00"
generated_at: "2026-09-18T21:14:06.232562+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# InMed receives Nasdaq delisting notice for equity shortfall; merger to cure

## Summary
- Nasdaq notice on 9/16/2026: shareholders' equity $1,075,007 vs $2.5M required under Rule 5550(b)(1).
- 45 days to submit compliance plan (by Nov 2, 2026); up to 180-day extension possible until Mar 15, 2027.
- Deficiency driven by Merger expenses with Mentari; combined company expects ~$490M gross proceeds, closing Q4 2026.
- Stock up ~99.8% since Merger announcement; shares continue trading on Nasdaq under INM.

## SEC filing metadata
- accession: 0001213900-26-101492
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2026-09-18T21:11:43+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390026101492/0001213900-26-101492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390026101492/ea0305769-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-101492
- JSON: https://secwatch.observer/filing/0001213900-26-101492.json
- Plain text: https://secwatch.observer/filing/0001213900-26-101492.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.